Transgenomic to Reduce Headcount as Q3 Revenues Drop 12 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Transgenomic announced on Monday afternoon a consolidation of its R&D activities and a reduction in headcount as net sales for the third quarter fell 12 percent.

For the three months ended Sept. 30, the Omaha, Neb.-based company said sales shrank to $4.4 million, compared to $5.0 million in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.